All Releases
 |
Intellipharmaceutics Meets a 2012 Goal for Abuse-Deterrent Oxycodone
May 1, 2012
|
15.2 KB |
|
| |
TORONTO, May 1, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided an update on its research and development activities and achie...
|
|
Intellipharmaceutics Announces First Quarter 2012 Results
Apr 12, 2012
|
27.3 KB |
|
| |
TORONTO, April 12, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc.(Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of n...
|
|
Intellipharmaceutics Announces Webcast of Presentation at the 11th Annual Needham Healthcare Conference
Mar 27, 2012
|
13.8 KB |
|
| |
TORONTO, March 27, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief F...
|
|
Intellipharmaceutics Closes US$5,000,000 Registered Direct Offering of Common Shares
Mar 15, 2012
|
15.2 KB |
|
| |
TORONTO, March 15, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI)(TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has closed its previously announced registered dire...
|
|
Intellipharmaceutics to Raise US$5 Million
Mar 9, 2012
|
15.2 KB |
|
| |
TORONTO, March 9, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it is raising approximately US$5 million in a register...
|
|
Intellipharmaceutics to Present at Upcoming Cowen Healthcare and Roth Conferences
Feb 17, 2012
|
14.8 KB |
|
| |
TORONTO, Feb. 17, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI - News) (TSX:I), a pharmaceutical company specializing in the research, de...
|
|
Intellipharmaceutics Announces 2011 Year End Results
Feb 8, 2012
|
30.8 KB |
|
| |
TORONTO, Feb. 8, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI - News) (TSX:I), a pharmaceutical company specializing in the research, developme...
|
|
Intellipharmaceutics Appoints Vice President Business Development
Jan 30, 2012
|
14.2 KB |
|
| |
TORONTO, Jan. 30, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that its United States subsidiary, Intellipharmaceutics Ltd...
|
|
Intellipharmaceutics Announces Webcast of Presentation at the Biotech Showcase 2012
Jan 5, 2012
|
13.4 KB |
|
| |
TORONTO, Jan. 5, 2012 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Dr. Isa Odidi, CEO, will present a Company overview at ...
|
|
Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement
Nov 25, 2011
|
14.8 KB |
|
| |
TORONTO, Nov. 25, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has filed a preliminary short form base shelf pros...
|
|
Intellipharmaceutics Announces Webcast of Presentation at the 23rd Annual Piper Jaffray Healthcare Conference
Nov 23, 2011
|
13.4 KB |
|
| |
TORONTO, Nov. 23, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief Fi...
|
|
Intellipharmaceutics' Manufacturing Facility Passes FDA cGMP and Pre-Approval Inspection
Nov 15, 2011
|
14.5 KB |
|
| |
TORONTO, Nov. 15, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that its Toronto-based oral solid dosage forms manufacturi...
|
|
FDA Accepts for Filing Intellipharmaceutics' ANDA for Generic Lamictal® XR™
Oct 31, 2011
|
14.5 KB |
|
| |
TORONTO, Oct. 31, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI - News) (TSX:I) today announced the U.S. Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of Lamictal® XR...
|
|
Intellipharmaceutics Announces Third Quarter 2011 Results
Oct 7, 2011
|
28.7 KB |
|
| |
TORONTO, Oct. 7, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended...
|
|
Intellipharmaceutics Announces Webcast of Presentation at the JMP Securities Healthcare Conference
Sep 26, 2011
|
14.2 KB |
|
| |
TORONTO, Sept. 26, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that Shameze Rampertab, Vice President Finance and Chief F...
|
|
Intellipharmaceutics and Par Pharmaceutical Expand Development and Commercialization Agreement
Aug 18, 2011
|
14.4 KB |
|
| |
TORONTO, Aug. 18, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company and Par Pharmaceutical, Inc. (NYSE:PRX) ha...
|
|
Intellipharmaceutics Announces Second Quarter 2011 Results
Jul 5, 2011
|
29.4 KB |
|
| |
TORONTO, July 5, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended ...
|
|
Intellipharmaceutics Announces Settlement for Its Generic Version of Effexor XR(R)
Jun 21, 2011
|
14.4 KB |
|
| |
TORONTO, June 21, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced that Intellipharmaceutics and Wyeth LLC, a wholly owned subsidiary of Pfizer Inc., have settled the patent infringement litigation in the United States District Court for the Southern District of New York, relating to Intelliphar...
|
|
Intellipharmaceutics Provides Update on Activities Related to Generic Seroquel XR(R)
May 26, 2011
|
13.5 KB |
|
| |
TORONTO, May 26, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), today announced the following with regard to its generic drug commercialization activities.
AstraZeneca Pharmaceuticals LP and AstraZeneca UK Limited have filed suit for patent infringement against Intellipharmaceutics in the United States D...
|
|
FDA Accepts for Filing Intellipharmaceutics' ANDA for Generic Seroquel XR®
May 3, 2011
|
13.3 KB |
|
| |
TORONTO, May 3, 2011 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) today announced the U.S. Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of Seroquel XR® (quetiapine fumarate extended-release tablets). Seroquel XR® is an oral...
|
|
|
